norfloxacin has been researched along with Hepatopulmonary Syndrome in 3 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Hepatopulmonary Syndrome: A syndrome characterized by the clinical triad of advanced chronic liver disease, pulmonary vascular dilatations, and reduced arterial oxygenation (HYPOXEMIA) in the absence of intrinsic cardiopulmonary disease. This syndrome is common in the patients with LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was no major effect of norfloxacin on gas exchange in patients with hepatopulmonary syndrome." | 9.14 | Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. ( Bayoumi, AM; Faughnan, ME; Fowler, R; Gupta, S; Hutchison, S; Lilly, L, 2010) |
| "Hepatopulmonary syndrome was diagnosed after demonstration of the presence of a massive intrapulmonary shunt." | 1.31 | Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. ( Añel, RM; Sheagren, JN, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, S | 1 |
| Faughnan, ME | 1 |
| Lilly, L | 1 |
| Hutchison, S | 1 |
| Fowler, R | 1 |
| Bayoumi, AM | 1 |
| Rabiller, A | 1 |
| Nunes, H | 1 |
| Lebrec, D | 1 |
| Tazi, KA | 1 |
| Wartski, M | 1 |
| Dulmet, E | 1 |
| Libert, JM | 1 |
| Mougeot, C | 1 |
| Moreau, R | 1 |
| Mazmanian, M | 1 |
| Humbert, M | 1 |
| Hervé, P | 1 |
| Añel, RM | 1 |
| Sheagren, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome[NCT00362752] | Phase 2 | 9 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for norfloxacin and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Cross-Over Studies; Female; Hepatopulmonary Syndrome; Humans; Ma | 2010 |
2 other studies available for norfloxacin and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Translocation; Common Bile Duct; D | 2002 |
Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents.
Topics: Adult; Anti-Infective Agents; Brain Abscess; Hepatopulmonary Syndrome; Humans; Male; Nitric Oxide; N | 2001 |